TNF and COVID-19: Recently, published data from the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE) IBD registry provided valuable reassurance that immunosuppressant drugs, in particular anti-tumor necrosis factor agents (anti-TNFs), were not associated with adverse outcomes in IBD patients who developed COVID-19 [26].